Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lucanthone - Spectrum Pharmaceuticals

Drug Profile

Lucanthone - Spectrum Pharmaceuticals

Alternative Names: Lucanthone hydrochloride; Tixantone

Latest Information Update: 16 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Albert Einstein College of Medicine
  • Developer Spectrum Pharmaceuticals; University of Alabama at Birmingham
  • Class Antineoplastics; Antiparasitics; Radiosensitisers; Small molecules; Thioxanthenes; Xanthones
  • Mechanism of Action DNA apurinic apyrimidinic site lyase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain metastases; Breast cancer; Glioblastoma

Most Recent Events

  • 30 Jan 2018 Spectrum Pharmaceuticals withdraws a phase II trial in Brain metastases (Adjunctive treatment) in USA due to pending resolution of study drug issues (PO) (NCT02014545)
  • 10 Aug 2015 The University of Alabama at Birmingham and Spectrum Pharmaceuticals suspend a phase II trial in Brain metastases (Adjunctive treatment) in USA, as the principal investigator left the university (PO) (NCT02014545)
  • 30 Nov 2013 Phase-II clinical trials in Brain metastases in USA (PO)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top